Finally, strategies such as DNase I, antiproteases, anti-histone antibodies, and PAD inhibitors show promise in reducing NETs and could be explored for the treatment of IIM [47, 100]. This evidence concerns the gene DNASE1 and acquired idiopathic inflammatory myopathy.